Hologic, Inc. (NASDAQ:HOLX) Stake Boosted by Clean Yield Group

Clean Yield Group grew its stake in shares of Hologic, Inc. (NASDAQ:HOLX - Free Report) by 15.9% during the 1st quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 52,909 shares of the medical equipment provider's stock after acquiring an additional 7,263 shares during the period. Clean Yield Group's holdings in Hologic were worth $3,268,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also modified their holdings of HOLX. Smartleaf Asset Management LLC lifted its stake in shares of Hologic by 36.9% in the fourth quarter. Smartleaf Asset Management LLC now owns 590 shares of the medical equipment provider's stock valued at $43,000 after buying an additional 159 shares during the period. Capital Investment Counsel Inc lifted its stake in Hologic by 3.6% during the fourth quarter. Capital Investment Counsel Inc now owns 5,724 shares of the medical equipment provider's stock worth $413,000 after purchasing an additional 200 shares during the period. Dark Forest Capital Management LP lifted its stake in Hologic by 7.9% during the fourth quarter. Dark Forest Capital Management LP now owns 3,053 shares of the medical equipment provider's stock worth $220,000 after purchasing an additional 223 shares during the period. Baker Avenue Asset Management LP lifted its stake in Hologic by 0.5% during the fourth quarter. Baker Avenue Asset Management LP now owns 42,051 shares of the medical equipment provider's stock worth $3,031,000 after purchasing an additional 225 shares during the period. Finally, EverSource Wealth Advisors LLC lifted its stake in Hologic by 79.8% during the fourth quarter. EverSource Wealth Advisors LLC now owns 586 shares of the medical equipment provider's stock worth $42,000 after purchasing an additional 260 shares during the period. 94.73% of the stock is currently owned by hedge funds and other institutional investors.

Hologic Stock Performance

Shares of Hologic stock opened at $64.33 on Friday. The company has a debt-to-equity ratio of 0.52, a current ratio of 3.49 and a quick ratio of 2.78. The firm has a market cap of $14.34 billion, a P/E ratio of 20.29, a P/E/G ratio of 2.14 and a beta of 0.55. The firm has a 50 day simple moving average of $58.27 and a 200 day simple moving average of $65.35. Hologic, Inc. has a fifty-two week low of $51.90 and a fifty-two week high of $84.67.

Hologic (NASDAQ:HOLX - Get Free Report) last issued its quarterly earnings results on Thursday, May 1st. The medical equipment provider reported $1.03 earnings per share for the quarter, beating analysts' consensus estimates of $1.02 by $0.01. The business had revenue of $1.01 billion during the quarter, compared to analyst estimates of $1 billion. Hologic had a net margin of 18.42% and a return on equity of 19.72%. Hologic's revenue for the quarter was down 1.2% compared to the same quarter last year. During the same quarter last year, the business posted $1.03 earnings per share. Sell-side analysts predict that Hologic, Inc. will post 4.28 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Hologic news, Director Martin D. Madaus bought 5,445 shares of the stock in a transaction on Wednesday, May 7th. The stock was purchased at an average price of $55.24 per share, with a total value of $300,781.80. Following the acquisition, the director now owns 5,445 shares of the company's stock, valued at approximately $300,781.80. The trade was a ∞ increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Company insiders own 1.88% of the company's stock.

Analyst Ratings Changes

A number of research analysts have commented on the stock. Needham & Company LLC restated a "hold" rating on shares of Hologic in a research note on Tuesday, May 27th. Morgan Stanley cut their price target on shares of Hologic from $77.00 to $65.00 and set an "equal weight" rating for the company in a research note on Monday, May 5th. Wall Street Zen cut shares of Hologic from a "buy" rating to a "hold" rating in a research note on Monday, May 5th. Royal Bank of Canada cut their price target on shares of Hologic from $75.00 to $70.00 and set a "sector perform" rating for the company in a research note on Friday, May 2nd. Finally, Raymond James reiterated an "outperform" rating and issued a $71.00 target price (down previously from $90.00) on shares of Hologic in a research note on Friday, May 2nd. Twelve research analysts have rated the stock with a hold rating, five have assigned a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, the company currently has an average rating of "Hold" and an average price target of $77.42.

About Hologic

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.